Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US FDA clears Calidi’s CLD-201 for clinical development in solid tumours
This clearance is intended for treating solid tumours in adults, with a focus on head & neck cancer, breast cancer and soft tissue sarcoma. Preclinical data included in
This clearance is intended for treating solid tumours in adults, with a focus on head & neck cancer, breast cancer and soft tissue sarcoma. Preclinical data included in
The funding round was spearheaded by CTI Life Sciences Fund, Advent Life Sciences, and abrdn-managed funds. Current investors, including Sanofi Ventures, Novo Holdings, RiverVest Venture Partners, Sanderling Ventures,
This transaction is said to be contingent on receiving customary regulatory approvals. Theravia’s portfolio includes Siklos for sickle cell disease and Orphacol for genetic disorders affecting the liver’s
This collaboration primarily aims to concentrate on expediting production of the recessive dystrophic epidermolysis bullosa (RDEB) therapy CORDStrom. An independent technology and innovation organisation, CGT Catapult focuses on
The partnership will leverage Nona’s two heavy and two light chain (H2L2) Harbour Mice platforms to detect next-generation therapeutic candidates. The platform employs transgenic mice to produce fully
Spearheaded by Deep Track Capital, this funding round saw participation from new investors, including Catalio Capital Management, Cytokinetics, and AN Ventures, alongside contributions from current backers SV Health
This follows the company’s February announcement of a definitive merger agreement signed with BioSymetrics. This merger aims to bolster Renovaro’s data analysis and biomarker discovery capabilities, while also
France 2030 is a selective French government initiative to fast-track “breakthrough innovations”. The funding is an endorsement of 4MB, achieved through a multi-stage assessment by experts in science,
This decision is based on the randomised MITIGATE trial data, which showed the antibody’s potential to reduce disease activity by minimising flares in individuals, upholding its established safety
This clearance comes after the company’s receipt of approval from New Zealand’s Medsafe last month for clinical trial application to commence a first-in-human study of the therapy. During